Mr CHAN (pseudonym, right), an NPC patient, states that his physical condition and life quality were not seriously affected during immunotherapy, and that he suffered fewer side effects than with chemotherapy.

Abstract

Our researchers led an international study that demonstrated the anti-tumour activity of the immune-checkpoint inhibitor in recurrent and metastatic nasopharyngeal cancer (NPC) patients. Results showed the 1-year overall survival rate to be around 60%. Further analysis facilitated the identification of biomarkers and the development of immunotherapy in NPC patients. The findings of this landmark study have been published in the Journal of Clinical Oncology.

Details: http://bit.ly/2G1E7eP